A clinical trial is a research study that finds new ways to treat a disease. The Arkansas Urology Research Center (AURC) participates in several clinical research trials to offer therapies to our patients that are not yet available at other local practices or clinics in Arkansas. These clinical trials are available to men and women of all ages.
You’ll find a few studies that we are actively enrolling our patients in listed below. We have additional studies not listed. Please contac the AURC at 501-219-8900 if you are interested in learning more about these studies and/or other research opportunities.
Prostate Cancer
GREGOR DIAGNOSTICS *Semen Collection at the Time of Prostate Biopsy
The purpose of this research is to see if a new, experimental blood test might help men with prostate cancer who are on active surveillance need fewer prostate needle biopsies.
A blood sample is collected in Little Rock at the lab or at the surgery center prior to your biopsy.
Observational Study of Patients of Being Treated ORGOVYX
Relugolix Versus Leuprolide in Patients with Prostate Cancer: A Randomized, Open-Label Study to Assess Major Adverse Cardiovascular Events (REPLACE-CV)
A Randomized, Controlled, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer, Assessed by PSMA-PET, with an Observational Cohort
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide with Continued Versus Intermittent Androgen-Deprivation Therapy (ADT) following PSA Response in Participants with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
Bladder Cancer
High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC)
Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants with BCG-naïve High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC)
Janssen is conducting a Phase 2, Open-Label, Multi-Center, Randomized Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Scheduled for Radical Cystectomy and Are Ineligible for or Refusing Platinum-Based Neoadjuvant Chemotherapy.
A Phase 1, open-label trial of belzupacap sarotalocan (AU-011) to determine the feasibility and safety of intramural injection with or without intratumoral injection in subjects with non-muscle invasive bladder cancer (NMIBC)
High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC)
A Phase 1, Open-label, Dose-escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of UGN-301 (zalifrelimab) Administered Intravesically as Monotherapy and in Combination with Other Agents in Patients with Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)
Blood Collection at the Time of Prostate Biopsy
High Risk Hormone Sensitive Prostate Cancer
